Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO).

ENI Pelvic irradiation Pelvic nodal treatment Prostate carcinoma Radiotherapy

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
25 Jan 2024
Historique:
received: 11 12 2023
accepted: 17 12 2023
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 25 1 2024
Statut: aheadofprint

Résumé

For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.

Identifiants

DOI: 10.1007/s00066-023-02193-4 PMID: 38273135
pubmed: 38273135
doi: 10.1007/s00066-023-02193-4
pii: 10.1007/s00066-023-02193-4
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Caravatta L, Sallustio G, Pacelli F et al (2012) Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol 7:86
pubmed: 22691275 pmcid: 3494529 doi: 10.1186/1748-717X-7-86
Cheng YJ, Jing SW, Zhu LL et al (2018) Comparison of elective nodal irradiation and involved-field irradiation in esophageal squamous cell carcinoma: a meta-analysis. J Radiat Res 59(5):604–615
pubmed: 30085197 pmcid: 6151636 doi: 10.1093/jrr/rry055
Mensour EA, Alam S, Mawani S et al (2022) What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials. Front Oncol 12:1067321
pubmed: 36620554 pmcid: 9816564 doi: 10.3389/fonc.2022.1067321
Miller JA, Toesca DAS, Baclay JRM et al (2022) Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation. Int J Radiat Oncol Biol Phys 112(1):131–142
pubmed: 34348171 doi: 10.1016/j.ijrobp.2021.07.1698
Cozzi S, Botti A, Timon G et al (2022) Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for iymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol 198(8):700–709
pubmed: 34757443 doi: 10.1007/s00066-021-01871-5
Mottet N, van den Bergh RCN, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243–262
pubmed: 33172724 doi: 10.1016/j.eururo.2020.09.042
Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Eng J Med 360(24):2516–2527
doi: 10.1056/NEJMoa0810095
Lawton CAF, Lin X, Hanks GE et al (2017) Duration of androgen deprivation in locally advanced prostate cancer: long-term update if NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 98(2):296–303
pubmed: 28463149 pmcid: 5603177 doi: 10.1016/j.ijrobp.2017.02.004
Zapatero A, Guerrero A, Maldonado X et al High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet 16(3):320–327
Joseph D, Denham JW, Steigler A et al (2020) Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR trial. Int J Radiat Oncol Biol Phys 106(4):693–702
pubmed: 32092343 doi: 10.1016/j.ijrobp.2019.11.415
Pilepich MV, Krall JM, Johnson RJ et al (1986) Extended field (paraaortic) irradiation in carcinoma of the prostate—analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 12(3):345–351
pubmed: 3514555 doi: 10.1016/0360-3016(86)90349-4
Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2,B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15(6):1307–1316
pubmed: 3058656 doi: 10.1016/0360-3016(88)90225-8
Lawton CA, DeSilvio M, Roach M 3rd (2007) and al.: An updated of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655
pubmed: 17531401 pmcid: 2917177 doi: 10.1016/j.ijrobp.2007.04.003
Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate cancer? Preliminary results of GETUG-01. J Clin Oncol 25(34):5366–5373
pubmed: 18048817 doi: 10.1200/JCO.2006.10.5171
Pommier P, Chabaud S, Lagrange JL et al (2016) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96:759–769
pubmed: 27788949 doi: 10.1016/j.ijrobp.2016.06.2455
Roach M, Moughan J, Lawton CAF et al (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localized prostate cancer (NRG/RTOG 9413): long-term results of a randomized, phase 3 trial. Lancet 19(11):1504–1515
doi: 10.1016/S1470-2045(18)30528-X
Dearneley D, Griffin CL, Lewis R et al (2019) Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localized prostate cancer (PIVOTAL). Int J Radiat Oncol Biol Phys 103:605–617
doi: 10.1016/j.ijrobp.2018.10.003
Murthy V, Maitre P, Kannan S et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 39(11):1234–1242
pubmed: 33497252 doi: 10.1200/JCO.20.03282
Xie W, Regan MM, Buyse MM et al (2017) Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35:3097–3104
pubmed: 28796587 pmcid: 5652387 doi: 10.1200/JCO.2017.73.9987
Mendez LC, Arifin AJ, Bauman GS et al (2020) Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial. BMC Cancer 20:978
pubmed: 33036579 pmcid: 7547418 doi: 10.1186/s12885-020-07490-0
Sandler KA, Cook RR, Ciezki JP et al (2020) Prostate-only versus whole-pelvis radiation with or without a brachytherapy boost for Gleason grade group 5 prostate cancer: a retrospective analysis. Eur Urol 77:3–10
pubmed: 30992160 doi: 10.1016/j.eururo.2019.03.022
Tharmalingam H, Tsang Y, Choudhury A et al (2020) External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 106:525–533
pubmed: 31610249 doi: 10.1016/j.ijrobp.2019.09.044
Spratt DE, Vargas HA, Zumsteg ZS et al (2017) Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol 71:37–43
pubmed: 27523595 doi: 10.1016/j.eururo.2016.07.043
Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomized, multicenter study. Lancet 395:1208–1216
pubmed: 32209449 doi: 10.1016/S0140-6736(20)30314-7
Niazi T, Nabid A, Malagon T et al (2023) Hypofractionated, dose escalation radiation therapy for high-risk prostate cancer: the safety analysis of the prostate cancer study‑5, a groupe de radio-oncologie génito-urinaire de quebec led phase 3 trial. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2023.05.014
doi: 10.1016/j.ijrobp.2023.05.014 pubmed: 37224928
Niazi T, Nabid A, Malagon T et al (2022) Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer. In: 2022 ASTRO Annual Meeting, vol 4 (Presented October 23)
Syndikus I, Cruickshank C, Staffurth J et al (2020) PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). Clin Transl Radiat Oncol 25:22–28
pubmed: 32995575 pmcid: 7508714
Hope TA, Eiber M, Armstrong WR et al (2021) Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 7(11):1635–1642
pubmed: 34529005 pmcid: 8446902 doi: 10.1001/jamaoncol.2021.3771
Reis Ferreira M, Khan A, Thomas K et al (2017) Phase 1/2 dose-escalation study of the use of intensity modulated radiation therapy to treat the prostate and pelvic nodes in patients with prostate cancer. Int J Radiat Oncol Biol Phys 99(5):1234–1242
pubmed: 28939224 pmcid: 5697895 doi: 10.1016/j.ijrobp.2017.07.041
Abdollah F, Karnes RJ, Suardi N et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32(35):3939–3947
pubmed: 25245445 doi: 10.1200/JCO.2013.54.7893
Tilki D, Preisser F, Tennstedt P et al (2017) Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int 119(5):717–723
pubmed: 27743493 doi: 10.1111/bju.13679
Jegadeesh N, Liu Y, Zhang C et al (2017) The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. Cancer 123(3):512–520
pubmed: 27859018 doi: 10.1002/cncr.30373
Tilki D, Chen MH, Wu J et al (2022) Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J Clin Oncol 40(20):2186–2192
pubmed: 35290082 pmcid: 9273369 doi: 10.1200/JCO.21.02800
Ramey SJ, Agrawal S, Abramowitz MC et al (2018) Multi-institutional evaluation of elective nodal irradiation and/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer. Eur Urol 74(1):99–106
pubmed: 29128208 doi: 10.1016/j.eururo.2017.10.009
Song C, Byun SJ, Kim YS et al (2019) Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: a propensity score matching analysis. PLoS ONE 14(4):e215057
pubmed: 30973905 pmcid: 6459518 doi: 10.1371/journal.pone.0215057
Kucharczyk MJ, Tsui JMG, Khosrow-Khavar F et al (2020) Combined long-term androgen deprivation and pelvic radiotherapy in the post-operative management of pathologically defined high-risk prostate cancer patients: results of the prospective phase II McGill 0913 study. Front Oncol 10:312
pubmed: 32226774 pmcid: 7080953 doi: 10.3389/fonc.2020.00312
Pollack A, Karrison TG, Balogh AG et al (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399(10338):1886–1901
pubmed: 35569466 pmcid: 9819649 doi: 10.1016/S0140-6736(21)01790-6
Meijer D, Eppinga WSC, Mohede RM et al (2022) Prostate-specific membrane antigen positron emission tomography/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. Eur Urol Oncol 5(2):146–152
pubmed: 35074282 doi: 10.1016/j.euo.2022.01.001
Rogowski P, Trapp C, von Bestenbostel R et al (2022) Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging 49(4):1417–1428
pubmed: 34628521 doi: 10.1007/s00259-021-05557-z
Solomonidou N, Germanou D, Strouthos I et al (2023) PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA 〈 0.2 ng/ml. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-023-06185-5
doi: 10.1007/s00259-023-06185-5 pubmed: 36905411 pmcid: 10250454
Zamboglou C, Peeken JC, Janbain A et al (2023) Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open 6(5):e2314748
pubmed: 37219907 pmcid: 10208140 doi: 10.1001/jamanetworkopen.2023.14748
Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417–428
pubmed: 28146658 pmcid: 5444881 doi: 10.1056/NEJMoa1607529
Carrie C, Magné N, Burban-Provost P et al (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 20(12):1740–1749
pubmed: 31629656 doi: 10.1016/S1470-2045(19)30486-3
Ghadjar P, Koerber SA, Hölscher T et al (2022) The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy. Lancet 400(10356):883–884
pubmed: 36116475 doi: 10.1016/S0140-6736(22)01440-4
Kahvecioglu A, Yilmaz MT, Hurmuz P (2022) The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy. Lancet 400(10356):884–885
pubmed: 36116476 doi: 10.1016/S0140-6736(22)01488-X
Turco F, Gillessen S, Bosetti DG et al (2022) The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy. Lancet 400(10356):885
pubmed: 36116478 doi: 10.1016/S0140-6736(22)01482-9
Grabenbauer F, Flentje M (2022) Salvage prostate bed radiotherapy: co-irradiation of regional LNs and significance of ADT. Strahlenther Onkol 198(12):1119–1121
pubmed: 36083310 pmcid: 9700569 doi: 10.1007/s00066-022-02001-5
Ghadjar P, Aebersold DM, Albrecht C et al (2018) Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlenther Onkol 194(7):619–626
pubmed: 29383406 doi: 10.1007/s00066-018-1269-3
Van den Broeck T, van den Bergh RCN, Arfi N et al (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol 75(6):967–987
pubmed: 30342843 doi: 10.1016/j.eururo.2018.10.011
Dees RT, Sun Y, Jackson WC et al (2020) Association of presalvage radiotherapy PSA levels after prostatectomy with outomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol 6(5):735–743
doi: 10.1001/jamaoncol.2020.0109
Parker CC, Clarke N, Cook A et al (2022) Duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial. Ann Oncol 33(7):S1427
doi: 10.1016/j.annonc.2022.08.064

Auteurs

S A Koerber (SA)

Department of Radiation Oncology, Barmherzige Brüder Hospital Regensburg, Prüfeninger Straße 86, 93049, Regensburg, Germany. stefan.koerber@barmherzige-regensburg.de.
Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. stefan.koerber@barmherzige-regensburg.de.

S Höcht (S)

Department of Radiation Oncology, Ernst von Bergmann Hospital Potsdam, Charlottenstraße 72, 14467, Potsdam, Germany.

D Aebersold (D)

Department of Radiation Oncology, Inselspital-Bern University Hospital, University of Bern, Freiburgstraße 4, 3010, Bern, Switzerland.

C Albrecht (C)

Nordstrahl Radiation Oncology Unit, Nürnberg North Hospital, Prof.-Ernst-Nathan-Str. 1, 90149, Nürnberg, Germany.

D Boehmer (D)

Department of Radiation Oncology, University Hospital Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

U Ganswindt (U)

Department of Radiation Oncology, University Hospital Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.

N-S Schmidt-Hegemann (NS)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany.

T Hölscher (T)

Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Fiedlerstraße 19, 01307, Dresden, Germany.

A-C Mueller (AC)

Department of Radiation Oncology, RKH Hospital Ludwigsburg, Posilipostraße 4, 71640, Ludwigsburg, Germany.

P Niehoff (P)

Department of Radiation Oncology, Sana Hospital Offenbach, Starkenburgring 66, 63069, Offenbach, Germany.

J C Peeken (JC)

Department of Radiation Oncology, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany.

M Pinkawa (M)

Department of Radiation Oncology, Robert Janker Klinik, Villenstraße 8, 53129, Bonn, Germany.

B Polat (B)

Department of Radiation Oncology, University Hospital Würzburg, Josef-Schneider-Straße 11, 97080, Würzburg, Germany.

S K B Spohn (SKB)

Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Straße 3, 79106, Freiburg, Germany.

F Wolf (F)

Department of Radiation Oncology, Paracelsus Medical University of Salzburg, Müllner Hauptstraße 48, 5020, Salzburg, Austria.

C Zamboglou (C)

Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Straße 3, 79106, Freiburg, Germany.
German Oncology Center, 1, Nikis Avenue, Agios Athanasios, 4108, Limassol, Cyprus.

D Zips (D)

Department of Radiation Oncology, University Hospital Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

T Wiegel (T)

Department of Radiation Oncology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.

Classifications MeSH